We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+44.05%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$250M
Cap. Flow
+$59M
Cap. Flow %
5.51%
Top 10 Hldgs %
62.56%
Holding
47
New
20
Increased
3
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$71.3M
2
UTHR icon
United Therapeutics
UTHR
+$69.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$67.9M
4
GMED icon
Globus Medical
GMED
+$52.3M
5
KROS icon
Keros Therapeutics
KROS
+$35.1M

Top Sells

Rank Stock Value
1
APTO
Aptose Biosciences, Inc.
APTO
+$48M
2
MRSN
Mersana Therapeutics
MRSN
+$46M
3
CGEN icon
Compugen
CGEN
+$42.9M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$36.4M
5
APRE icon
Aprea Therapeutics
APRE
+$35.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.27%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$26.2B
$80.3M 7.5%
+528,964
New +$69.4M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$2.09B
$79.4M 7.41%
+1,710,803
New +$67.9M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$72.5M 6.77%
+330,000
New +$71.3M
TCRR
4
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$71.3M 6.66%
584,885
-924,934
-61% -$23.4M
ATRA icon
5
Atara Biotherapeutics
ATRA
$73.6M
$69.3M 6.48%
141,310
-46,111
-25% -$21.3M
GNMK
6
DELISTED
GenMark Diagnostics, Inc
GNMK
$65.4M 6.11%
4,480,163
-819,700
-15% -$10.9M
SWTX
7
DELISTED
SpringWorks Therapeutics
SWTX
$64.8M 6.05%
893,499
+290,767
+48% +$18.7M
GMED icon
8
Globus Medical
GMED
$10.9B
$59.3M 5.54%
+908,953
New +$52.3M
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.92B
$55M 5.14%
2,729,709
+360,000
+15% +$7.75M
MGNX icon
10
MacroGenics
MGNX
$240M
$52.6M 4.91%
2,299,829
-1,447,469
-39% -$33.3M
KROS icon
11
Keros Therapeutics
KROS
$202M
$39.3M 3.67%
+557,095
New +$35.1M
MRSN
12
DELISTED
Mersana Therapeutics
MRSN
$37.3M 3.48%
56,068
-82,659
-60% -$46M
ARVN icon
13
Arvinas
ARVN
$536M
$36.1M 3.37%
+425,000
New +$14.7M
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
$30.5M 2.85%
7,349,621
-6,657,927
-48% -$26.3M
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$27.7M 2.58%
+484,671
New +$28.7M
GMDA
16
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$27.6M 2.58%
+3,287,745
New +$22.2M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$1.95B
$27.4M 2.55%
+631,215
New +$25M
IMGN
18
DELISTED
Immunogen Inc
IMGN
$22.7M 2.12%
+3,515,944
New +$20.5M
CASI
19
DELISTED
CASI Pharmaceuticals
CASI
$22.4M 2.09%
757,643
+101,643
+15% +$2.21M
VSTM icon
20
Verastem
VSTM
$536M
$16.6M 1.55%
+648,349
New +$13M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.4M 1.53%
2,373,924
-1,471,070
-38% -$9.41M
STXS icon
22
Stereotaxis
STXS
$133M
$16M 1.49%
3,135,176
– –
ASMB icon
23
Assembly Biosciences
ASMB
$516M
$11.9M 1.11%
164,156
– –
CHFW.U
24
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$10.5M 0.98%
+1,000,000
New +$10.2M
RCUS icon
25
Arcus Biosciences
RCUS
$3.55B
$10.1M 0.94%
+387,492
New +$9.38M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Consonance Capital Management held 47 positions worth $1.07B, up 30% from $821M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Consonance Capital Management deployed $59M of net new capital in Q4 2020, opening 20 new positions and adding to 3 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 330,000 shares worth $72.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Mersana Therapeutics, an estimated $46M trimmed.

  • Consonance Capital Management's largest Q4 2020 buy was Mirati Therapeutics, Inc. Common Stock: 330,000 shares worth $72.5M.
  • Consonance Capital Management added most to SpringWorks Therapeutics in Q4 2020, an estimated $18.7M increase.
  • Consonance Capital Management's biggest Q4 2020 reduction was Mersana Therapeutics, cutting an estimated $46M.
  • Consonance Capital Management fully exited Aptose Biosciences, Inc. in Q4 2020, selling an estimated $48M.
  • Consonance Capital Management's ten largest holdings make up 63% of its $1.07B portfolio in Q4 2020.
  • Consonance Capital Management opened 20 new positions and closed 9 in Q4 2020.
  • Consonance Capital Management's portfolio value rose 30% quarter-over-quarter to $1.07B.

Based on Consonance Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.